Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1648718 | 0.83 | SLC22A6 (0.39) | ALOX15TSHRTDP1LMNAMAPT | |
| SCHEMBL6806491 | 0.82 | ALDH1A1 (0.53) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL28160177 | 0.82 | ALDH1A1 (0.44) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL8308112 | 0.82 | ALDH1A1 (0.53) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL6809972 | 0.82 | ALDH1A1 (0.53) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL11050299 | 0.80 | ALOX15 (0.46) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL6057628 | 0.79 | KMT2A (0.37) | ALOX15TSHRTDP1KMT2ALMNA | |
| SCHEMBL1480202 | 0.79 | KMT2A (0.37) | ALOX15TSHRTDP1KMT2ALMNA | |
| SCHEMBL11050300 | 0.78 | ALDH1A1 (0.39) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL11147040 | 0.78 | ALDH1A1 (0.41) | ALDH1A1ALOX15CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108617-A1 | AUTO-TUNING DRUG REGULATOR CONSTRUCTIONS | RETHINK64 BIONETWORKS PBC (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2024155707-A1 | AUTO-TUNING DRUG REGULATOR CONSTRUCTIONS | RETHINK64 BIONETWORKS PBC (US) | 2024-07-25 | — | — | WO | disclosed |
| EP-0758312-B1 | SUBSTITUTED FUSED AND BRIDGED BICYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | LILLY CO ELI (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0946515-A1 | PARASITICIDAL PYRAZOLES | Pfizer Limited (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024767-A1 | PARASITICIDAL PYRAZOLES | PFIZER LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| EP-0758312-A4 | SUBSTITUTED FUSED AND BRIDGED BICYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | LILLY CO ELI (US) | 1997-09-10 | — | — | EP | disclosed |
| EP-0758312-A1 | SUBSTITUTED FUSED AND BRIDGED BICYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ELI LILLY AND COMPANY (US) | 1997-02-19 | — | — | EP | disclosed |
| US-5583221-A | ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS, VIRICIDES, FUNGICIDES | ELI LILLY AND COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| WO-1996005729-A1 | VICINAL-SUBSTITUTED CARBOCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ELI LILLY AND COMPANY (US) | 1996-02-29 | — | — | WO | disclosed |
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995030640-A1 | SUBSTITUTED FUSED AND BRIDGED BICYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ELI LILLY AND COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
| US-5432198-A | Enzyme inhibitors | SPHINX PHARMACEUTICALS CORPORATION (US) | 1995-07-11 | — | — | US | disclosed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108617-A1 | AUTO-TUNING DRUG REGULATOR CONSTRUCTIONS | TPMT, CYP2D6, ACHE | ALDH1A1 1207/4885ALOX15 3079/4885CYP3A4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.